
Zydus Lifesciences has gained final approval from the US Food and Drug Administration (USFDA) to market a generic contraceptive medication. The approved drug, Norelgestromin and Ethinyl Estradiol Transdermal System (150 mcg/35 mcg per day) is a combination hormone medication designed to prevent pregnancy. Zydus Lifesciences will manufacture the transdermal patch at its Moraiya facility in Ahmedabad. According to IQVIA MAT data, the drug generated annual sales of USD 330 million in the US market.
Like
Save
Share